Treos Bio updates results of phase 1/2 trial of its cancer vaccine
Category: #health  By Paroma Bhattacharya  Date: 2019-09-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

Treos Bio updates results of phase 1/2 trial of its cancer vaccine

Vaccine-specific T cell responses were initially anticipated by PEPI test (via the complete HLA genotype of patient).

Treos Bio Ltd. has reportedly updated positive outcomes on the second segment of phase 1/2 trial (OBERTO) along with PolyPEPI1018 cancer injection. The second part of the trial is a supplement to the company’s maintenance treatment in patients suffering from microsatellite stable (MSS) metastatic colorectal cancer (mCRC).

Apparently, the phase 1/2 study is a single-arm, open-label, multicenter trial. The trial aims to evaluate the tolerability, safety, preliminary efficacy, and immunogenicity of single dose or multiple doses of PolyPEPI1018. The doses are intended as a supplement to maintenance treatment in subjects suffering from metastatic colorectal cancer following the first-line induction chemotherapy. Initial outcomes from the first part of the trial were exhibited at ASCO 2019 and outcomes of the second part have been made available now.

Reportedly, patients with mCRC in first line setting were given up to three dosages of PolyPEPI1018 vaccine (0.2 mg/peptide) 12 weeks apart. Doses were given following the transition to maintenance treatment with bevacizumab and fluoropyrimidine. Vaccine-specific T cell responses were initially anticipated by PEPI test (via the complete HLA genotype of patient). Later, these responses were calculated after one series of vaccination.

Joleen M. Hubbard, M.D., principal investigator of the OBERTO study, Mayo Clinic, reportedly stated that in addition to the unforeseen tumor responses examined for a few of the patients, it has been very reassuring that most of the subjects on multiple doses controlled their disorder till the completion of the follow-up time and beyond. The investigators have planned to continue registration of more patients in the trial and follow them for an even extended interval this time, she further added.

Reports confirm that in addition to the presentation of poster of the OBERTO study outcomes, three more posters will be displayed by Treos Bio at ESMO 2019. Those extra posters will be associated with its PEPI based platform technology and science.

Source credits:

https://finance.yahoo.com/news/treos-bio-reports-updated-positive-091500643.html



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...